Evidence map›Paper›PMID 41196228›Full record

ArticleJournal of medicinal chemistry2025

Novel Dimeric Capsid Assembly Modulators as a Unique Class of Highly Potent Anti-HBV Agents.

Franck Amblard, Zhe Chen, Kalouna Kra, Dharmeshkumar Patel, Leda Bassit, Laetitia Gargowitsch, Jéril Degrouard, Virgile Rat, Ana-Andreea Arteni, Lauren Matthews and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Franck AmblardCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.ORCID 0009-0002-6235-4050
Zhe ChenCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Kalouna KraUniversité Paris-Saclay, CNRS, Laboratoire de Physique des Solides, 91405 Orsay, France.
Dharmeshkumar PatelCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.ORCID 0000-0003-1601-256X
Leda BassitCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Laetitia GargowitschUniversité Paris-Saclay, CNRS, Laboratoire de Physique des Solides, 91405 Orsay, France.
Jéril DegrouardUniversité Paris-Saclay, CNRS, Laboratoire de Physique des Solides, 91405 Orsay, France.ORCID 0000-0001-5024-4255
Virgile RatMorphogenèse et Antigénicité du VIH et des Virus des Hépatites, Inserm - U1259 MAVIVH, Hôpital Bretonneau, Tours 75018, France.
Ana-Andreea ArteniUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France.
Lauren MatthewsEuropean Synchrotron Radiation Facility, 38043 Grenoble, France.ORCID 0000-0001-8843-5794
Shreya M RavichandranCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.ORCID 0009-0007-4960-3194
Alfred JiangCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Antonis AthanasiadisCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Georgios DangasCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Maedot AbateCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Guillaume TressetUniversité Paris-Saclay, CNRS, Laboratoire de Physique des Solides, 91405 Orsay, France.
Julien PronostInternational Center for Research in Infectiology (CIRI), INSERM U1111, Université Claude Bernard Lyon, CNRS, UMR5308, ENS, Lyon 69365, France.
Mohammad SalmanCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Kiran VermaCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Karen A KirbyCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.ORCID 0000-0003-2468-4796
Eleftherios MichailidisCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Hugues de RocquignyMorphogenèse et Antigénicité du VIH et des Virus des Hépatites, Inserm - U1259 MAVIVH, Hôpital Bretonneau, Tours 75018, France.
David DurantelInternational Center for Research in Infectiology (CIRI), INSERM U1111, Université Claude Bernard Lyon, CNRS, UMR5308, ENS, Lyon 69365, France.
Stéphane BressanelliUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France.
Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
Raymond F SchinaziCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.ORCID 0000-0002-6688-3614

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
HBV Capsid EffectorsR01AI132833 · NIAID · EMORY UNIVERSITY · PI Raymond Felix Schinazi · 2017 to 2026
$5.3M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8M
Altering Hepatitis B Virus assembly through pharmacological interventionR01AI148740 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI GUMBART, JAMES C. · 2020 to 2024
$2.0M
Novel Antivirals Targeting Lenacapavir-Resistant HIVF31AI194923 · NIAID · EMORY UNIVERSITY · PI Shreya Meenakshi Ravichandran · 2025 to 2026
$100k
NIAID NIH HHS F31 AI194923NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI132833NIAID NIH HHS R01 AI148740NIGMS NIH HHS T32 GM135060
6 · The paper itself

Abstract

Approximately 250 million people are chronic HBV carriers and are at high risk of developing hepatitis, cirrhosis, and hepatocellular carcinoma. Several drugs are currently approved, but because they do not cure, lifelong therapies are the norm. HBV capsid assembly modulators (CAMs) have emerged as a promising option, as they lower several key markers of HBV replication. Novel dimeric structures (D-CAMs) were designed and evaluated. Their potency and mechanism of action were compared to those of monomeric D-CAMs, such as GLP-26. Among them, D-CAM-14 exhibited improved potency over GLP-26 and a unique effect on capsid morphology and kinetic assembly.

Indexed as

Antiviral AgentsCapsidHepatitis B virusVirus AssemblyCapsid ProteinsDimerizationHep G2 CellsHumansStructure-Activity RelationshipVirus ReplicationAntiviral AgentsCapsid Proteins

Identifiers

PMID41196228
PMCPMC13077713

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.